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Abstract
Objectives To develop a training programme to enable pharmacists with pre-
scribing rights to assume responsibility for the provision of pharmaceutical care
within care homes, a systematic review and narrative synthesis was undertaken
to identify reported approaches to training pharmacists and use this literature
to identify potential knowledge requirements.
Methods A PROSPERO-registered systematic review was performed using key
search terms for care homes, pharmacist, education, training and pharmaceuti-
cal care. Papers reporting primary research focussed on care of the older person
within the care home setting were included. No restrictions were placed on
methodology. Two researchers independently reviewed titles, abstracts and
papers. Agreement on inclusion was reached through consensus. Data on titles,
training and activities undertaken were extracted and knowledge requirements
identified. Findings were synthesised and reported narratively.
Key findings Fifty-nine papers were included, most of which were uncontrolled
service evaluations. Four papers reported an accreditation process for the phar-
macist. Thirteen papers reported providing tools or specific training on a single
topic to pharmacists. The main clinical and therapeutic areas of activity (requir-
ing codified knowledge) were dementia, pain, antipsychotic and cardiovascular
medication. Provision of pharmaceutical care, effective multidisciplinary working
and care home staff training represented the main areas of practical knowledge.
Conclusions Information regarding training and accreditation processes for
care home pharmacists is limited. This study provides insight into potential
codified and practical knowledge requirements for pharmacists assuming
responsibility for the provision of pharmaceutical care within care homes. Fur-
ther work involving stakeholders is required to identify the cultural knowledge
requirements and to develop a training and accreditation process.
Background
The Care Homes’ Use of Medicines Study (CHUMS)
reported in 2009 that almost 70% of UK care home resi-
dents experienced at least one medication error on any
given day.[1] The authors proposed that the fundamental
failings were largely due to the fact that no single health-
care professional had overall continuing responsibility for
medicines management.[1] The UK Department of Health
Immediate Action Alert arising from CHUMS required
© 2019 The Authors. International Journal of Pharmacy Practice
published by John Wiley & Sons Ltd on behalf of Royal Pharmaceutical Society
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
International Journal of Pharmacy Practice 2020, 28, pp. 207--219
International Journal of
Pharmacy Practice
Research Paper
International Journal of Pharmacy Practice 2020, 28, pp. 207–219
primary care organisations, general practitioners (GPs)
and pharmacy contractors to establish effective joint
working strategies to address the identified concerns.[2]
The resultant predominant model of care was that of a
pharmacy team undertaking medication reviews in care
homes on a yearly or twice-yearly basis. A recent
Cochrane review conducted by Alldred et al.,[3] which
considers the international literature where similar phar-
macy services have been described, suggests that current
models are sub-optimal and more effective approaches to
medicines optimisation in this setting are required.
Changes in UK legislation, enabling suitably trained
pharmacists to prescribe,[4] provide an opportunity for
pharmacist-independent prescribers (PIPs) to assume the
proposed central role in the care home environment. Evi-
dence from the UK[5] and other countries[6] suggests that
pharmacist-independent prescribers can prescribe safely
and provide patient benefit.[7]
The model of a pharmacist assuming responsibility for
medicines-related activities in care homes would be simi-
lar to that mandated in the United States whereby a phar-
macist is required to be an integral part of the care home
team where they develop, implement and monitor indi-
vidualised medicines-focussed (pharmaceutical) care
plans.[8] However, in the United States, the pharmacist is
not responsible for prescribing and is reliant on the care
home physician to implement identified medication
changes.
To achieve prescribing status in the UK, pharmacist-in-
dependent prescribers (PIPs) are required to demonstrate
competency against a national framework which consists
of generic competencies that are applicable to all prescrib-
ing activities.[9] During the training and accreditation
process, PIPs are also expected to identify their clinical
area of defined practice, develop competence within the
area and practise within it.
In 2012, the UK National Institute for Healthcare
Research (NIHR) funded a programme to develop and
test the concept of PIPs assuming responsibility for the
provision of pharmaceutical care within the care home
environment (CHIPPS) via a randomised controlled
trial.[10] The service was planned to involve, as a mini-
mum, the pharmacist working closely with a resident’s
GP to enable them to assume responsibility for authorisa-
tion of repeat prescriptions. This responsibility would
then enable PIPs to support all medicines-related pro-
cesses within the home (medicines ordering, storage,
administration, review and monitoring) as envisaged by
the National Institute of Health and Care Excellence
(NICE),[11] Royal Pharmaceutical Society (RPS)[12] and
researchers.[1]
To enable PIPs to operate safely and effectively
within care homes and enhance intervention fidelity,[13]
a training programme and accreditation process were
required with content based on the education and
training needs for the role identified from the published
literature. Eraut separates workplace knowledge into
three distinct types, and these were used to structure
our approach: codified (that written down); practical
(skills required to perform tasks); and cultural (that
required to work effectively within the location, that is
understanding of local expectations, standards and prac-
tices).[14]
Thus, the aim of this systematic review, regarding inter-
national literature relating to the employment of pharma-
cists within care homes, was to capture previously
reported approaches to training and use this literature to
identify potential codified, practical and cultural knowl-
edge requirements for the role.
Method
The systematic review was registered with PROSPERO
(CRD42015026693) and is reported according to
PRISMA.[15] Papers and abstracts were selected for review
in order to inform both content and design of any future
pharmacist training package.
The target population was registered pharmacists pro-
viding a medication-related intervention to care homes.
For controlled studies, any comparator, for example usual
care or enhanced medication management provided by
another healthcare professional, was eligible. Papers
reporting any primary research of any study design and
any secondary research were included.
Synonyms for care home (population), pharmacist (in-
tervention), education and training (outcome) and phar-
maceutical care (intervention) were used. Dates of
publications were until 31 July 2019.
Inclusion criteria were as follows:
• Description of education and training of pharmacists
prior to service/intervention delivery in a care home,
OR
• Description of expertise of the pharmacist, for example
title denoting additional expertise or training to per-
form role, OR
• Training provided by pharmacists to care home staff
for which they would need to have sufficient knowledge
to deliver, OR
• Materials provided to support the pharmacist in service
delivery in care homes, AND
• English language publication.
Exclusion criteria were as follows:
• Studies not primarily focussed on provision of services
to older people residing in care homes, that is palliative
care services, children services or HIV, those not pri-
marily based within the care home setting, OR
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• Studies located in care homes where the primary focus
was to determine the effectiveness of an individual drug
rather than a pharmacy service, for example pharmaco-
logical studies, OR
• Papers without empirical data, for example editorials,
opinion pieces, commentaries, OR
• Abstracts, OR Systematic reviews and narrative synthe-
ses.
Databases searched were Academic Search Complete,
EbscoH, Ovid MEDLINE(R) and EMBASE, OvidSP,
ASSIA (Applied Social Sciences Index and Abstracts),
CSA, ProQuest XML, Cochrane Database of Systematic
Reviews, Cochrane Reviews, E-theses online service
(EThOS), Ingentaconnect.com (Ingenta), Wiley Online
Science, EPOC Group Specialised Register, Reference
Manger, Ageline (EbsoH), CINAHL (Cumulative Index to
Nursing and Allied Health Literature), EbsoH, Interna-
tional Pharmaceutical Abstract (OvidSP) and PsycINFO
(EbsoH).
No date limit was used for article selection. Our proto-
col search strategy is provided in Appendix S1.
Titles, abstracts and full papers were screened for eligi-
bility against inclusion and exclusion criteria, indepen-
dently, by two authors. Decisions were compared and
differences resolved by consensus. The need for a third
independent reviewer did not occur.
For the purposes of the search, we defined a care home as
being somewhere, other than the individual’s home, which
provides community-based accommodation and 24-hour
care for people who are unable to live independently.
The number of titles, abstracts and papers identified at
each stage was recorded to populate the PRISMA dia-
gram15 and Kappa coefficient[16] calculated at each stage.
The quality of included papers was not appraised. As
this was a narrative synthesis focussed on learning from
the content of published care home interventions, we
were not interested in outcomes of the intervention per se
or the development of an understanding of the relation-
ship between the two.
In line with Cochrane guidance, the following informa-
tion was extracted: from papers and abstracts by two
independent researchers:
• Year study reported
• Study design
• Location, for example country
• Setting as described within the paper
• Description of the main findings
• To provide insight into accreditation, training and sup-
port provision (where provided):
○ Description of pharmacist expertise
○ Description of education and training provided to
pharmacists
○ Description of tools used to support service delivery
• Description of training of care staff provided by phar-
macist (codified knowledge)
• Clinical area(s) of focus, for example dementia (codi-
fied knowledge)
• Therapeutic area(s) of focus, for example antipsychotics
(codified knowledge)
• Intervention description, that is what they did and
focus, for example medicines reconciliation (practical
knowledge)
• For therapeutic and clinical areas, up to three of the
most commonly reported in each paper were extracted.
The clinical and therapeutic areas were developed as
data extraction proceeded; that is, as new areas were iden-
tified, they were added to the database. Results were com-
pared and again agreed by consensus by two independent
reviewers.
One reviewer (DW) additionally read the background
and discussions in all papers to identify any additional
comments relating to education and training of the phar-
macists, which could be used to either provide insight
into cultural knowledge requirements or further informa-
tion relating to codified or practical knowledge require-
ments.
Analytical approach
Data were themed by Eurat domains and collated to
inform the development of a care home pharmacist train-
ing plan. All training methods were extracted. The results
were then narratively synthesised.
Results
Paper selection and description
Figure 1 provides a summary of the paper identification
process. The level of agreement between independent
reviewers at title, abstract and paper stage was 90.8%,
81.2% and 92.3% with Kappa values of 0.117, 0.134 and
0.839, respectively.
Table 1 summarises the characteristics of the 59 included
papers. The majority of studies were located in the United
States,[17–41] UK[42–49] and Australia[50–56] with smaller
numbers from the Netherlands,[57–59] Canada[60–62] and
Belgium.[63–65] Twelve papers reported randomised con-
trolled trials,[27,32,39,44–46,48,50,53,54,66,67] and five were non-
randomised controlled studies,[21,38,41,56,64,68,69] with the
remainder pre-/post-uncontrolled interventions conducted
as service evaluations. Papers ranged in publication dates
from 1978 to 2019, and all services reported positive
outcomes with respect to their main aim.
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Pharmacist, education and training
characteristics
Thirteen papers stated that the pharmacist delivering the
service was a ‘consultant’,[18,19,21,22,25,29,30,32,39–41,60,69] and
twelve papers noted that the pharmacist was described as
‘clinical’.[18,20,23,33,35,36,38,56,58,62,64,70] Five papers reported
that the pharmacist had completed an accreditation pro-
cess,[24,27,52,56,65] one of which[65] described the training
as consisting of consultation skills, identification of drug-
related problems, guidelines and how to create pharma-
ceutical care plans. Two papers stated that the pharmacist
had a postgraduate clinical qualification.[46,50]
Six papers reported the pharmacists being provided
with a tool to support the service, and these included the
medication stopping (STOPP) and medication initiation
(START) tools[64,66], Geriatric Risk Assessment MedGuide
(GRAM) software,[32] Dader method of pharmacotherapy
Figure 1 PRISMA diagram for literature review process.
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follow-up,[69] Beers criteria,[71] GheOP-S tool,[72] antipsy-
chotic use survey tool[73] and other unspecified toolk-
its.[26,74]
Two papers described the pharmacists being trained in
inter-professional relationship development[31,47] and in
how to perform medication review.[46,65] Individual papers
described using an online package focussed on the use of
methotrexate,[34] training on falls prevention,[32] medicines
administration[63] and the use of antipsychotics.[30] Train-
ing provided to staff in care homes by pharmacists included
use of antipsychotics,[30,37] medicines administration,[59,63]
pain management[28,43,50] and inter-professional communi-
cation.[47]
Codified and practical knowledge
Table 2 provides a summary of the main clinical and thera-
peutic areas identified and the most commonly cited activi-
ties. The main areas of ‘codified knowledge’ regarding
appropriate use of medicines and management of conditions
used by pharmacists are reported in order of frequency of
appearance. The main activities reported and coded as ‘prac-
tical knowledge requirements’ related to the service are simi-
larly listed and included medication review, discontinuation,
change, monitoring and initiation. The ability to work in a
multidisciplinary manner and train others were also com-
monly cited activities which require practical knowledge.
The importance of good inter-professional working skills
and development of effective relationships with homes were
identified in four papers[40,52,62,64] and with general practi-
tioners in one.[43] Care home staff training was identified as
an important element in developing those relation-
ships.[24,50]
Cultural knowledge
Care home staff training was seen as important for changing
care home medicines-related cultures, for example requests
for medication such as antibiotics, antipsychotics, analgesia
and laxatives[50] and willingness to implement changes in
therapy. Care home culture was cited in one paper as a rea-
son for medicines changes not being implemented.[50]
Watching medicines administration and providing feedback
on errors[56] as well at routine attendance at ward rounds to
discuss antipsychotic medication use[38] were seen as effec-
tive at changing cultures.
Discussion
This is the first paper to systematically identify the
reported training associated with pharmacists employed
in care homes for older people and to then identify their
potential knowledge requirements. Whilst pharmacistTa
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activity within care homes has been reported in a large
number of countries, there seems to be relatively limited
evidence describing how they have been supported or
developed for this role. There was some recognition of
additional expertise or training required for the role
within a number of papers but how this was achieved or
accredited was largely not described.
The results suggest that knowledge related to an ageing
population, for example regarding the effective manage-
ment of dementia and pain, would be required for a
pharmacist undertaking a central medicines management
role in care homes. Additionally, they would need to be
able to routinely provide pharmaceutical care, demon-
strate an ability to work in multidisciplinary teams and
train care staff. Researchers have also suggested that
understanding local cultures and an ability to influence
them would be required.
The review was performed with a wide remit for inclu-
sion of papers with any content providing insight into
pharmacist training in the care home environment. This
may explain the lack of initial agreement between review-
ers in the first two stages. There was, however, good
agreement when the final papers were reviewed, and the
researchers were not required to make a subjective judge-
ment on paper content from the limited information
available in titles and abstracts. The large number of
papers from a wide variety of settings, countries and years
provided a good overview of the research evidence but
may miss the more mundane activities routinely under-
taken by pharmacists within care homes which may not
be believed to be worthy of publication. Similarly, the
clinical and therapeutic areas identified may reflect those
which are believed to be of greatest need or providing
greatest patient benefit, and therefore, frequency of report
is unlikely to align with frequency of activity within dif-
ferent areas. Without a time restriction on the search, we
have included some relatively old papers where knowledge
requirements for pharmacists may differ and we have not
considered the effect of this in our analysis. Similarly, lit-
erature reviews, by definition, look backwards and there-
fore provide little or no insight into future activities. New
models of pharmaceutical care within care homes include
the involvement of pharmacy technicians in some coun-
tries to undertake some of the routine tasks and improve
use of skill mix within this setting.[75] We have not con-
sidered this model of care or its impact on the training
needs of pharmacists. Increasingly, pharmacists are under-
taking clinical assessments and physical examinations[76]
and this knowledge may be necessary in this environment
in the not-too-distant future.
The lack of reported training suggests that there has
been limited consideration to date of training and accred-
iting pharmacists to provide pharmaceutical care within
care homes either for service delivery or trial design pur-
poses. Taking into consideration the frailty of the care
home population and the complexity of their needs, it is
surprising that additional training for the role has not
been largely considered. When designing evaluations of
complex interventions of this nature, careful consideration
of intervention fidelity to standardise intervention dose
(as far as is possible) is recommended.[77]
Similarly, due to a recent pharmacist-based study to
improve patient adherence resulting in significant patient
harm,[78] as with the development and testing of any new
complex intervention, it cannot be assumed that they are
safe. Within the proposed CHIPPS model, there is no
third party to moderate pharmacist interventions and
therefore it is important for both scientific and ethical
validity that pharmacists are appropriately trained and
accredited prior to service implementation. Where accred-
itation was reported as a requirement for service provi-
sion, a description of the process was largely not
provided. [24,27,52]
Individuals delivering the reported services were fre-
quently described using the terms ‘consultant’ and ‘clini-
cal’. Interestingly, neither term within the pharmacy
Table 2 Identified codified and practical knowledge requirements
Codified knowledge
Practical knowledge
Therapeutic area (n) Clinical area (n) Activity (n)
Psychotropic (18) Dementia (9) Medication review (46)
Cardiovascular (11) Pain (5) Medicines discontinuation (31)
Gastrointestinal (7) Diabetes (4) Medicines change (26)
Benzodiazepines (6) Cardiovascular disease (4) Monitoring recommendations (21)
Analgesia (4) Stroke (2) Multidisciplinary intervention (22)
Nutrition and blood (3) Dysphagia (3) Medicines initiation (12)
Anticoagulants (2) Infection (1) Care home staff training (13)
Antimicrobials (2) Behavioural problems (2) Error management (7)
Urinary tract (1) Pulmonary disease (1) Medicines reconciliation (4)
Falls prevention (1) Use STOPP/START tool (2)
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profession has internationally recognised education, train-
ing and accreditation processes to underpin them. In the
United States, there is a requirement for pharmacists
working within care homes to hold ‘consultant’ status;
however, there are no nationally recognised additional
education requirements above the Doctor of Pharmacy
(PharmD) held by pharmacists as standard.[79] The lack
of description of pharmacist training for operating within
care homes in the US literature may be due to the fact
that usual pharmacist training largely prepares them for
operating in this environment and the PharmD provided
in the United States, where students are taught to under-
take clinical roles,[80] may well be appropriate. The Amer-
ican Society of Consultant Pharmacists does provide
board certification in geriatric pharmacy, which consists
of undertaking a written examination, but does not
require this for an individual to adopt the title of consul-
tant pharmacist.[81] This is perhaps an implicit recogni-
tion of the need for certification but recognition that it
may be impractical to impose it.
During the screening process, we chose to include
papers where the term ‘clinical pharmacist’ was used
assuming that it may denote additional training. The
term, however, in a similar manner to ‘consultant phar-
macist’ is more commonly used to describe the role of
the pharmacist rather than their underpinning knowledge
and training.[82]
When considering the codified knowledge require-
ments, it is unsurprising that many interventions are
focussed on diseases related to ageing such as cardiovas-
cular and gastrointestinal conditions. Such topics are cen-
tral to pharmacist education and training, and therefore,
additional training may not be required. The inappropri-
ate and potentially harmful use of antipsychotic medica-
tion in care homes to manage the behavioural symptoms
associated with dementia has been widely reported.[82–85]
The initiation and safe discontinuation of antipsychotic
therapy in older persons may not form part of generic
pharmacist training. Similarly, the recent recognition of
the need to effectively manage pain in residents with
dementia to improve quality of life and minimise agita-
tion[85] may also explain the importance of focussing on
this topic within care homes, and is another area where
specific training may be required. The other areas that
may be more specific to the care home population and
require bespoke additional training are the management
of falls (linked to medication) and medicines administra-
tion for residents with dysphagia.
Where training was described, it usually focussed on
the delivery of one activity.[30,32,34,63] Similarly, tools and
toolkits were frequently provided to pharmacists to stan-
dardise the service or intervention.[26,32,40,41,64–66,69,74]
Provision of activity-focussed training and tools was
therefore generally without consideration of any addi-
tional training which may be required to enhance imple-
mentation in this environment. Impact can potentially be
enhanced through better inter-professional relationships,
understanding of the barriers to improving practice and
the implementation of enablers to address them.[24,50]
Although it was not a focus of this paper, a commonly
reported outcome was the number of pharmacist interven-
tions accepted and implemented by the responsible primary
care physician.[21,22,24–26,29,35,40,41,43,45,49,55,58,65,69,74,86] The
reliance on another professional to accept and implement a
pharmacist’s recommendations may partially explain the
focus on the development of inter-professional relation-
ships within pharmacist training in two of the papers. [31,47]
The deployment of a pharmacist with prescribing rights
within care homes removes the reliance on another profes-
sion; however, within the CHIPPS model, the resident’s GP
is still ultimately responsible for their care. Consequently, it
will be necessary for the pharmacist and GP to work
together effectively in order to both minimise duplication
of effort and prevent potential conflict.
Conclusion
Accepting that the systematic review did not include the
grey literature and is entirely dependent on published liter-
ature with empirical data, the information provided here
can only be used to form the basis of a training plan for
pharmacists operating within the care home environment.
Insight into the types of knowledge required by pharmacists
is provided but is limited by the fact that research publica-
tions, which by definition report novel and interesting
activities, may not include descriptions of routine activities
undertaken by pharmacists in this environment. A pharma-
cist assuming the central medicines management role
would be expected to contribute at all levels, and therefore,
extensive input from all relevant stakeholders is now
required to fully develop a training and accreditation pro-
cess, which is likely to be both practical and acceptable.
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